Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Clin Pharmacol Ther. 2018 Oct 18;105(3):703–709. doi: 10.1002/cpt.1233

Figure 1:

Figure 1:

Co-prescription of strong CYP1A2 inhibitors and the risk of tizanidine-associated severe hypotension, results stratified by modified Charlson scores

Results adjusted for age, sex, and race. Error bars represent odds ratios and 95% confidence intervals as compared to reference group (cyclobenzaprine and Charlson score = 0).